Maci 3CM x 5CM implant sheets
Ended Awarded
- Contract number
- SPE2DB26FYM53
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $61,903
Award facts
- Contract value 100% obligated
- $61,902.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $61,903 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The delivery order, issued on November 6, 2025, with an ultimate completion date of December 1, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. MACI (matrix-applied characterized autologous cultured chondrocytes) implants are specialized orthopedic surgical products used for cartilage repair and regeneration, representing a specialized medical consumable within the contractor's broader pharmaceutical and medical supply portfolio.
This delivery order was issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $500 million ceiling and extends through December 31, 2036. The PPV-G GEN V represents a $30.3 billion federal acquisition strategy designed to provide standardized pharmaceutical sourcing for Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across multiple product categories and therapeutic areas, including oncology treatments, biologics, vaccines, and specialty surgical products, demonstrates its capability to fulfill the diverse medical supply requirements of the military medical system.
Quick answers
Who was awarded contract SPE2DB26FYM53?
SPE2DB26FYM53 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DB26FYM53 worth?
The government has obligated $61,903 on SPE2DB26FYM53.
Is contract SPE2DB26FYM53 an order under another contract?
Yes. SPE2DB26FYM53 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM53 competed?
The extent of competition for SPE2DB26FYM53 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award